Clinical Trials on Pyruvatcarboxylase-Mangel

Total 2046 results

National Cancer Institute (NCI)

Completed

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Mantle Cell Lymphoma | Lymphoma, Mantle Cell

United States
Eli Lilly and Company

Completed

Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma

Mantle-Cell Lymphoma

Australia, France, Germany, Netherlands
Fondazione Italiana Linfomi ONLUS

Unknown

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients (MCL0208)

MANTLE CELL LYMPHOMA

Italy, Portugal
Janssen Pharmaceutical K.K.

Completed

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-cell

Japan
Heidelberg University

Unknown

Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma (HD-MCL2003)

Mantle-Cell Lymphoma

Germany
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
Weill Medical College of Cornell University

Completed

Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma

Untreated Mantle Cell Lymphoma

United States
The Lymphoma Academic Research Organisation
French Innovative Leukemia Organisation

Completed

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (T³)

Mantle Cell Lymphoma Refractory

France
Zhongshan Ophthalmic Center, Sun Yat-sen University

Not yet recruiting

Liwan Eye Study: the Fourth Follow-up

Primary Angle-Closure Glaucoma
Alcon Research

Completed

Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)

Angle-closure Glaucoma

United States
University of Alabama at Birmingham
National Institute on Aging (NIA)

Active, not recruiting

Impact of Glaucoma and Visual Field Loss on Life Space

Primary Open-angle Glaucoma

United States
Glaukos Corporation

Terminated

iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications

Primary Open Angle Glaucoma (POAG)

Brazil
Glaukos Corporation

Completed

One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects

Primary Open Angle Glaucoma (POAG)

Armenia
Implandata Ophthalmic Products GmbH

Completed

Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)

Primary Open-angle Glaucoma

Germany
Wills Eye

Completed

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

Primary Open-angle Glaucoma

United States
University of California, Los Angeles
National Eye Institute (NEI)

Active, not recruiting

Advanced Glaucoma Progression Study (AGPS)

Primary Open Angle Glaucoma | Chronic Angle Closure Glaucoma | Pseudoexfoliative Glaucoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell Lymphoma

United States
Ege University

Completed

Process Model of Emotion Regulation Integrated Musical Rhythm Interventions' Effects on Student Nurses' Anger

Anger

Turkey
naomi goldstein
National Institute of Mental Health (NIMH)

Completed

Effectiveness of Anger Management Treatment in Reducing Anger-Related Behaviors in Female Juvenile Offenders

Anger

United States
AbbVie

Active, not recruiting

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland, Russian Federation, South Africa, Sweden, United Kingdom
Jadran Galenski laboratorij d.d.

Completed

Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

Primary Open Angle Glaucoma of Both Eyes

Russian Federation
AbbVie

Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
iSTAR Medical

Enrolling by invitation

MINIject Implantation Combined With Cataract Surgery in Patients With POAG and Cataract (STAR-VI)

Cataract | Primary Open-angle Glaucoma

Spain, Panama, United Kingdom
Allergan

Completed

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Bausch & Lomb Incorporated

Completed

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension (LUNAR)

Ocular Hypertension | Open-Angle Glaucoma

United States
Bausch & Lomb Incorporated

Completed

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension (APOLLO)

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon Research
Novartis Institute for BioMedical Research

Completed

A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma

Ocular Hypertension | Open-Angle Glaucoma
Aerie Pharmaceuticals

Completed

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Glaukos Corporation

Completed

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost

Open-angle Glaucoma

Armenia
Glaukos Corporation

Completed

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

Primary Open-angle Glaucoma

United States
Merck Sharp & Dohme LLC

Completed

Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Military Institute of Medicine, Poland

Unknown

Safety and Efficacy of Three Variants of Canaloplasty With Phacoemulsification to Treat Glaucoma and Cataract

Primary Open Angle Glaucoma, Cataract

Poland
Allergan

Completed

A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
FinnMedi Oy
Tampere University; The Laboratory and Pharmacy Public Utility of the Pirkanmaa...

Completed

The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma

Ocular Hypertension | Open-Angle Glaucoma

Finland
Alcon Research

Completed

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Alcon Research

Completed

A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Safety and Efficacy of Travoprost/Timolol BAC-free

Ocular Hypertension | Open-Angle Glaucoma

Japan
Alcon Research

Completed

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Efficacy of Changing to TRAVATAN® From Prior Therapy

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Patient Preference Comparison of AZARGA Versus COSOPT

Ocular Hypertension | Open-Angle Glaucoma
Mati Therapeutics Inc.
QLT Inc.

Completed

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon Research

Completed

Travoprost 3-Month Safety and Efficacy Study

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Santen Oy

Completed

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

Ocular Hypertension | Open-angle Glaucoma

United States
Alcon Research

Completed

Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Santen Oy

Completed

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

Ocular Hypertension | Open-angle Glaucoma

Hungary

3

Subscribe